clesitamig (RG6524) / Roche - LARVOL DELTA

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (clinicaltrials.gov) - P1 | N=122 | Recruiting | Sponsor: Chugai Pharmaceutical | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (clinicaltrials.gov) - P1 | N=122 | Not yet recruiting | Sponsor: Chugai Pharmaceutical

New P1 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas (clinicaltrials.gov) - P1 | N=41 | Completed | Sponsor: Hoffmann-La Roche | Recruiting ➔ Completed | N=168 ➔ 41 | Trial completion date: Sep 2025 ➔ Mar 2025 | Trial primary completion date: Sep 2025 ➔ Mar 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Endocrine Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor

A DLL3/CD3/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models (AACR 2023) - "We therefore developed a DLL3/CD3/CD137 trispecific T cell engager composed of two CD3/CD137 dual specific Fabs and one extra DLL3 Fab (DLL3 trispecific, RG6524). We initially investigated the CD3 and CD137 signal transduction in Jurkat cells harboring NFAT or NF-κB reporter cocultured with DLL3 positive cells...Likewise, tocilizumab treatment did not reduce the efficacy, suggesting that CRS mitigation did not abrogate the therapeutic benefit.We finally assessed the tolerability in non-human primates. Our data showed that DLL3 trispecific has potent activity and is well suited for clinical application in SCLC. These findings provide a rationale for the clinical testing of DLL3 trispecific."

IO biomarker • Preclinical • Trispecific • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • CD8 • DLL3 • IFNG • NF-κβ • TNFRSF9

"And 6 new projects in the clinic for $RHHBY, incl 2 undisclosed mechanisms in oncology: RG6524 (=RO7616789) FPI Jan 2023 https://t.co/qNRZpOUvjW RG6411 (=RO7502175) FPI Q4 2022 https://t.co/p48EaRVy85" (@JacobPlieth)

Oncology

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas (clinicaltrials.gov) - P1 | N=168 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting

Enrollment open • Endocrine Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas (clinicaltrials.gov) - P1 | N=168 | Not yet recruiting | Sponsor: Hoffmann-La Roche

New P1 trial • Endocrine Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor